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Singer ME, Beaird H, Miller LAN
Case Western Reserve University, Cleveland, OH, USA
BACKGROUND: Decision analytic models typically
compare strategies using expected values, which assumes
risk neutrality in all situations for all individuals. OB-
JECTIVE: Examine how risk attitude is affected by the
magnitude of the risk involved, and by the sociodemo-
graphic characteristics of the patient. METHODS: A set
of 5 related standard gambles was created. In all of them
the patient has an asymptomatic disease that will cause
painless death in 5 years. The only treatment is a pill that
only works if taken immediately. If successful, the patient
will live for 15 years. The 5 scenarios correspond to 0–4
years until death in the event of treatment failure. The
probability of failure was varied to establish the break-
even point. The expected break-even point was calculated
based on expected values. Risk attitude was measured us-
ing the Risk Attitude Ratio (RAR), the ratio of the indi-
vidual’s break-even point to the expected break-even
point. RAR  1 indicates perfect risk neutrality, with
lower values indicating risk adversity. Regression models
for each scenario were constructed for RAR, with regres-
sors based on age, race, sex, education, income and mari-
tal status. Additionally, a hierarchical linear model was
constructed using data from all 5 scenarios. RESULTS:
167 people were surveyed. Significant risk adversity was
observed in all scenarios. Mean break-even points ranged
from .07–.35. When treatment failure meant immediate
death, risk aversity was great with no statistically signifi-
cant associations. As time until death increased, RAR in-
creased (less risk averse) and was associated with sex,
race and marital status. These associations were upheld
in the overall model. Males and the previously married
were less risk averse. African-Americans were more risk
averse. CONCLUSIONS: Risk attitude varies according to
the specifics of the gamble as well as sociodemographics.
Assumptions of risk neutrality may be particularly poor
in cases where treatment failure carries a severe penalty.
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OBJECTIVE:
 
 In multinational trials, hospital costing is
estimated by assigning diagnosis- and country-specific
unit cost estimates to hospitalizations. Using this method-
ology, the standard error for hospitalization costs is un-
derestimated. Our objective is to expand methods for in-
ternational hospital costing to increase the validity of
hospitalization costs and to explore the effects of using
different methodologies on statistical power. METH-
ODS: In this analysis, ‘standard’ costing methodology as-
signs a fixed cost to each hospitalization. The ‘expanded’
methodology involves: (1) using DRG weights to adjust
country-specific cost estimates for diagnoses for which
cost data were not collected; (2) differentiating between
costs that occur on the day of admission and all remain-
ing hospital days; and (3) adjusting cost estimates by
length of stay for each hospitalization. Using data from a
subset of placebo-treated patients enrolled in a multina-
tional study of a new treatment for heart failure, we com-
pared estimates of total hospitalization costs using ‘stan-
dard’ and ‘expanded’ methodologies. RESULTS: Total
hospitalization costs were estimated for 200 patients who
had at least one hospitalization during the follow-up pe-
riod (mean  1.42). Using ‘standard’ and ‘expanded’
methods, average total costs were $5,911 and $5,881, re-
spectively. The corresponding standard errors were $269
and $417, an increase of 55% resulting in a loss of
power. Assuming homoskedasticity, equal sample size,
P  0.05, 2-sided t-test, and a $500 difference in costs,
one would have 25.7% power using ‘standard’ costing
methods but only 13.5% when using ‘expanded’ meth-
ods. With a $1,000 difference, one would have 74.5%
and 39.3% power, respectively. CONCLUSIONS: The
results of a cost comparison between treatment strategies
can be affected by the methodology used to calculate
costs. Studies that consider the intensity of hospital care,
or that consider the variability in resource utilization, re-
quire a larger sample size than studies that don’t consider
these issues to have equal power.
